This article was sponsored by Johnson & Johnson. Give your patients a chance to live longer without progression with TECVAYLI® + DARZALEX® compared to DPd/DVd1 ... Dieser Inhalt ist nur für Benutzer der Gruppe: Medizinische Fachperson zugänglich Jetzt beitretenAlready a member? Log in here
View Post 5 min This content is machine translated Sponsored Content: Pulmonary hypertension Also consider pulmonary hypertension in case of unexplained shortness of breath! Unexplained breathlessness is a frequent and challenging problem in the daily practice of general practitioners, pulmonologists and cardiologists. One possible underlying clinical picture is pulmonary hypertension (PH), which is often...…
View Post 1 min This content is machine translated Online training Swiss Oncology in Motion Module Prostate Cancer Treatment options for prostate cancer have evolved rapidly over the past two years, with advances across the spectrum of disease stages. Prof. em. Dr. med Richard Herrmann speaks in the… CME-Test
View Post 1 min This content is machine translated Swiss Oncology in Motion SOiM Urothelial carcinoma – Update Oncology is constantly changing, with additional diagnostic procedures, new surgical methods and innovative therapeutic concepts being developed. For this reason, the treatment guidelines are also continuously revised. Therefore, this module… CME-Test
View Post 8 min This content is machine translated Sponsored Content Personalized therapy for recurrent urinary tract infections Urinary tract infections are the most common bacterial infection in women and pose a major challenge both in everyday practice and in the clinic. Women have a significantly higher risk…
View Post 7 min This content is machine translated Interview with Prof. Thomas Kündig (USZ) and Prof. Diego Kyburz (USB) “You have to stop treating psoriasis as just a skin disease”. In Switzerland, psoriasis affects about 1 to 3 percent of the population [1]. About one in three psoriasis patients also suffers from psoriatic arthritis (PsA), a chronic inflammatory systemic disease that...…
View Post 5 min This content is machine translated Sponsored Content: Atopic dermatitis: Roadshow 2024 Better standard of care through joint decision-making The first Swiss Atopic Dermatitis (AD) Roadshow took place at the beginning of February 2024. AD expert Prof. Jonathan Silverberg from the George Washington University School of Medicine and Health…
View Post 4 min This content is machine translated Metastatic Merkel cell carcinoma Successful treatment with immunotherapy Chemotherapy (ChT) has always been the standard of care for the treatment of metastatic Merkel cell carcinoma (mMCC), but response rates are often not sustained [1, 2]. Bavencio® (avelumab) is…
View Post 3 min This content is machine translated Advanced hormone-sensitive prostate cancer Sustained testosterone reduction without injections Since January 1, 2024, the oral GnRH antagonist Relugolix has been approved in Switzerland for the treatment of adults with advanced hormone-sensitive prostate cancer [1, 2]. This gives patients access…
View Post 4 min This content is machine translated Chronic lymphocytic leukemia (CLL) One year of first-line therapy for CLL for the prospect of more than 5 years of treatment freedom¹ The BCL2 inhibitor venetoclax has been approved in Switzerland as a first-line therapy for chronic lymphocytic leukemia (CLL) since November 16, 2023 [2]. This is based on the results of…
View Post 5 min This content is machine translated SGDV Congress 2023: Psoriasis and atopic dermatitis On the trail with Sherlock Holmes and CSI – Mystery cases solved At the “somewhat different” AbbVie Symposium at this year’s Swiss Dermatology Congress (SGDV Congress) in Lausanne, experts did some excellent detective work: a missing person was found and the mysteriously…
